Talk:Survivin

From Wikipedia, the free encyclopedia

	This article is part of WikiProject Genetics, an attempt to build a comprehensive and detailed guide to genetics on Wikipedia. If you would like to participate, you can edit this page, or visit the project page to join the project and/or contribute to the discussion.
???	This article has not yet received a rating on the quality scale.
???	This article has not yet received an importance rating.

	This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess.
Start	This page has been rated as Start-Class on the quality assessment scale
Low	This article has been rated as Low-importance on the importance assessment scale

This article is currently or was the subject of an educational assignment.

Is it really fair to say that inhibiting survivin is not a feasible goal for anticancer therapy? Aurora Kinase inhibitors (especially inhibitors of AurkB) would perform exactly this function by preventing phosphorylation of survivin, thus inhibiting survivin function in its mitotic capacity. Furthermore, just because a proposed therapy would likely damage healthy rapidly-dividing cells certainly has not been a historical reason to preclude its use. 5-FU for example has been highly successful, despite the fact that it prevents mitosis of virtually every cell in the body. In general, the toxicity profile for chemotherapeutics has been caegorically poor- a fact the FDA allows becasue the alternative is almost certain death by untreated cancer. I think the aside about inhibition of survivin not being a practical target should at least be referenced if not removed. Wingsfan6047 (talk) 19:44, 12 April 2008 (UTC)